OM
Opaleye Management Portfolio holdings
AUM
$494M
This Quarter Return
-20.98%
1 Year Return
+68.17%
3 Year Return
+608.37%
5 Year Return
+807.76%
10 Year Return
+24,567.29%
AUM
$322M
AUM Growth
+$322M
(-32%)
Cap. Flow
-$26.8M
Cap. Flow
% of AUM
-8.31%
Top 10 Holdings %
Top 10 Hldgs %
58.84%
Holding
48
New
9
Increased
13
Reduced
15
Closed
3
Top Buys
| 1 |
BCYC
Bicycle Therapeutics
BCYC
|
$7.68M |
| 2 |
Fulcrum Therapeutics
FULC
|
$3.22M |
| 3 |
908 Devices
MASS
|
$3.16M |
| 4 |
Edgewise Therapeutics
EWTX
|
$2.94M |
| 5 |
Mersana Therapeutics
MRSN
|
$2.83M |
Top Sells
| 1 |
Celldex Therapeutics
CLDX
|
$22.1M |
| 2 |
Cytokinetics
CYTK
|
$6.39M |
| 3 |
BridgeBio Pharma
BBIO
|
$5.47M |
| 4 |
Semler Scientific
SMLR
|
$5.05M |
| 5 |
Sutro Biopharma
STRO
|
$4.85M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Ocular Therapeutix
OCUL
$2.12B
| $29.6M | 9.18% | 5,974,800 | – | – |
|
2
Codexis
CDXS
$246M
| $27.7M | 8.61% | 1,345,000 | – | – |
|
|
CMRX
3
DELISTED
Chimerix, Inc.
CMRX
| $27M | 8.4% | 5,903,450 +323,450 | +6% | +$1.48M |
|
4
Harrow
HROW
$1.44B
| $22.4M | 6.97% | 3,291,343 +6,343 | +0.2% | +$43.3K |
|
5
Crinetics Pharmaceuticals
CRNX
$2.92B
| $15.2M | 4.72% | 693,000 -31,400 | -4% | -$689K |
|
|
6
Cytokinetics
CYTK
$4.23B
| $15M | 4.65% | 406,500 -173,500 | -30% | -$6.39M |
|
7
Keros Therapeutics
KROS
$618M
| $14.5M | 4.49% | 265,750 | – | – |
|
8
Protara Therapeutics
TARA
$120M
| $13.7M | 4.24% | 2,674,031 +24,031 | +0.9% | +$123K |
|
|
RETA
9
DELISTED
Reata Pharmaceuticals, Inc. Class A Common Stock
RETA
| $13.3M | 4.14% | 407,002 +77,002 | +23% | +$2.52M |
|
10
Kiniksa Pharmaceuticals
KNSA
$2.48B
| $11.1M | 3.43% | 1,112,500 +87,500 | +9% | +$870K |
|
11
Eton Pharmaceutcials
ETON
$464M
| $10.4M | 3.22% | 2,379,275 -5,725 | -0.2% | -$25K |
|
12
Merus
MRUS
$4.98B
| $8.94M | 2.78% | 338,000 +20,200 | +6% | +$534K |
|
13
Stereotaxis
STXS
$261M
| $8.94M | 2.78% | 2,395,600 -130,900 | -5% | -$488K |
|
|
TCON
14
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
| $8.3M | 2.58% | 3,155,098 +100,098 | +3% | +$263K |
|
|
BCYC
15
Bicycle Therapeutics
BCYC
$511M
| $7.68M | 2.38% | +175,000 | New | +$7.68M |
|
16
Xoma
XOMA
$392M
| $7.58M | 2.36% | 271,000 -67,350 | -20% | -$1.88M |
|
|
17
Celldex Therapeutics
CLDX
$1.47B
| $6.66M | 2.07% | 195,500 -648,500 | -77% | -$22.1M |
|
18
Protagonist Therapeutics
PTGX
$3.67B
| $5.96M | 1.85% | 251,500 -90,500 | -26% | -$2.14M |
|
19
TELA Bio
TELA
$70.5M
| $5.55M | 1.72% | 477,000 +27,133 | +6% | +$316K |
|
20
Fortress Biotech
FBIO
$76.8M
| $5.1M | 1.58% | 3,750,000 | – | – |
|
21
Vaxcyte
PCVX
$4B
| $5.1M | 1.58% | 211,000 -104,800 | -33% | -$2.53M |
|
22
4D Molecular Therapeutics
FDMT
$288M
| $4.91M | 1.53% | 325,000 +96,000 | +42% | +$1.45M |
|
23
Larimar Therapeutics
LRMR
$310M
| $3.82M | 1.19% | 943,702 +60,100 | +7% | +$243K |
|
24
Ginkgo Bioworks
DNA
$750M
| $3.75M | 1.16% | 929,780 | – | – |
|
|
25
Semler Scientific
SMLR
$439M
| $3.47M | 1.08% | 70,000 -102,000 | -59% | -$5.05M |
|